Given the preferential effect of signaling via OX-40 on CD4+ and 4-1BB on CD8+ T cells [34] and the importance of both of these cell types for the generation of effective immune responses, a combinatorial use of agonists for these two receptors bears significant therapeutic potential for cancer and chronic infections. The gene discussed is TNFRSF4; the disease is cancer.